ClinicalTrials.gg

Program

ABSK061

A development code. Also written as “ABSK061 + ABSK043” and “ABSK061+ABSK043 in combination with CAPOX”.

Its studies are mostly in Achondroplasia · Carcinoma, Transitional Cell, led by Abbisko Cayman.

Furthest: phase 2, since Oct 1, 20244 company-led studies, 3 open or runningNext primary completion: Dec 15, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbisko Cayman43 open or runningphase 2since Oct 1, 2024Jan 12, 2022Dec 15, 2028phase 2 · NCT07297875

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 12, 2022First study: phase 1 study in Solid TumorFirst studyNCT05244551 · 85 planned · United States, China
  2. Oct 1, 2024Phase 2 study in Carcinoma, Transitional CellNCT06632262 · 202 planned · China
  3. May 14, 2025Phase 1 study in HealthyNCT07007546 · 42 enrolled · China
  4. Nov 24, 2025Phase 2 study in AchondroplasiaNCT07297875 · 110 planned · China

Ahead

  1. Dec 15, 2028Primary completion: phase 2 study in AchondroplasiaNCT07297875
  2. Nov 30, 2029Primary completion: phase 2 study in Carcinoma, Transitional CellNCT06632262

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07297875Achondroplasia · China2Not yet recruitingDec 15, 2028110
NCT07007546Healthy · China1CompletedJul 30, 202542
NCT06632262Carcinoma, Transitional Cell · China2RecruitingNov 30, 2029202
NCT05244551Solid Tumor · United States, China1RecruitingApr 30, 202585

How it is read

Names in the registry

  • “ABSK061”, 5 entries
  • “ABSK061 + ABSK043”, 1 entry
  • “ABSK061+ABSK043 in combination with CAPOX”, 1 entry

Codes read as this program: ABSK061.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.